12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Incivek regulatory update

FDA added a warning to the label for HCV drug Incivek telaprevir from Vertex about the potential for serious or life-threatening adverse reactions such as cardiac arrhythmias when used in combination with antipsychotic pimozide, an already contraindicated drug. FDA also added...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >